Ultimovacs ASA Unveils Significant Shareholder Changes Post Transactions

Overview of Ultimovacs ASA's Strategic Transactions

Ultimovacs ASA is making headlines with recent developments surrounding its business strategy. This month, the Company announced significant progress regarding its business combination with Zelluna Immunotherapy AS, coupled with a fully subscribed private placement, bringing in approximately NOK 51.7 million. These steps, collectively termed the Transactions, are set to reshape the shareholder landscape of Ultimovacs.

Insights from the Extraordinary General Meeting

In a pivotal moment for the Company, an extraordinary general meeting (EGM) took place to discuss crucial resolutions tied to the Transactions. The shareholders voted in favor of the issuance of a remarkable 167,864,598 new shares. This significant decision paves the way for notable changes in shareholdings among various stakeholders.

Major Shareholders and Their New Holdings

As Ultimovacs ASA moves forward with the Transactions, some key shareholders are on the brink of surpassing the critical threshold for shareholding disclosure as mandated by Norwegian law. This includes prominent names which will see their ownership stakes rise dramatically due to their actions during the private placement and business combination.

Geveran Trading Company's Expansion

Geveran Trading Company Ltd. is poised to make substantial gains with an allocation of 4,230,769 offer shares from the Private Placement. After receiving 20,847,543 shares in the Business Combination, Geveran will elevate its ownership to 25,078,312 shares, translating to approximately 12.4% of the Company.

Radforsk's Increased Shareholding

Radforsk is set to see its shareholding nearly double. Having received 1,038,461 offer shares, it will acquire an additional 22,156,490 shares in the Business Combination, elevating its total to about 24,714,214 shares and representing roughly 12.2% post-Transaction.

Inven2 AS Growth Prospects

Inven2 AS will also benefit significantly, initially acquiring 384,615 shares in the Private Placement and receiving 19,357,583 shares during the Business Combination. Their shareholding will escalate from 1,265,139 shares to about 21,007,337 shares, marking a prominent 10.4% ownership stake.

Impact on Gjelsten Holding AS

In contrast, Gjelsten Holding AS faces a reduction in its stake as it has been allocated 3,653,846 shares without any additional shares from the Business Combination. Its total ownership will decrease from 6,495,866 shares to approximately 10,149,712 shares, lowering their percentage from roughly 18.88% to 5.0%.

Takeda Ventures Joins the Ownership Ranks

Takeda Ventures, Inc. will be newly introduced to Ultimovacs’ shareholder roster, gaining 12,389,348 shares in the Business Combination, translating to about 6.1% ownership upon completion of the Transactions.

Birk Venture AS Contribution

Birk Venture AS will also enhance its position within the Company, receiving 538,461 offer shares and subsequently acquiring 14,196,604 shares from the Business Combination. By the end of these Transactions, their total shares will reach approximately 14,735,065, representing around 7.3% ownership.

Regulatory Compliance and Disclosure

It is important to note that these changes are subject to the disclosure requirements outlined in the Norwegian Securities Trading Act. Ultimovacs ASA remains committed to transparency and regulatory compliance as it navigates this transformative phase.

Frequently Asked Questions

What is the significance of the recent transactions for Ultimovacs ASA?

The recent transactions involve a substantial business combination with Zelluna Immunotherapy AS and a private placement, marking a transformative phase for the Company.

How will shareholder percentages change after the transactions?

Some shareholders will see significant increases in their ownership percentages due to allocations from the Private Placement and Business Combination, while others, like Gjelsten Holding AS, will experience a decrease.

What are the implications of the EGM's resolutions?

The EGM's approval of issuing new shares allows Ultimovacs ASA to proceed with their planned Transactions, fundamentally altering its shareholder structure.

Who are the key shareholders impacted by the transactions?

Key shareholders include Geveran Trading Company Ltd., Radforsk, Inven2 AS, Gjelsten Holding AS, Takeda Ventures, Inc., and Birk Venture AS, each experiencing shifts in their shareholdings.

Are there any regulatory implications tied to these transactions?

Yes, the transactions are subject to the disclosure requirements of the Norwegian Securities Trading Act, ensuring proper reporting and compliance.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.